Vapotherm, Inc. (VAPO)
USD 2.17
(-0.46%)
USD 2.17
(-0.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -39.08 Million USD | 49.54% |
| 2022 | -77.44 Million USD | -36.5% |
| 2021 | -56.73 Million USD | -31.9% |
| 2020 | -43.01 Million USD | 10.69% |
| 2019 | -48.16 Million USD | -29.36% |
| 2018 | -37.23 Million USD | -28.96% |
| 2017 | -28.87 Million USD | -29.91% |
| 2016 | -22.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -9.26 Million USD | -66.05% |
| 2024 Q1 | -5.58 Million USD | -10.98% |
| 2023 Q4 | -5.02 Million USD | 51.04% |
| 2023 Q2 | -10.15 Million USD | 54.68% |
| 2023 Q1 | -22.41 Million USD | -40.46% |
| 2023 Q3 | -10.27 Million USD | -1.13% |
| 2023 FY | -39.08 Million USD | 49.54% |
| 2022 Q4 | -15.95 Million USD | 22.0% |
| 2022 Q1 | -19.93 Million USD | -10.86% |
| 2022 FY | -77.44 Million USD | -36.5% |
| 2022 Q2 | -39.83 Million USD | -99.86% |
| 2022 Q3 | -20.45 Million USD | 48.65% |
| 2021 FY | -56.73 Million USD | -31.9% |
| 2021 Q3 | -12.88 Million USD | 22.4% |
| 2021 Q2 | -16.6 Million USD | -71.13% |
| 2021 Q1 | -9.7 Million USD | 21.23% |
| 2021 Q4 | -17.98 Million USD | -39.58% |
| 2020 FY | -43.01 Million USD | 10.69% |
| 2020 Q4 | -12.31 Million USD | -9.82% |
| 2020 Q1 | -12.71 Million USD | 0.03% |
| 2020 Q3 | -11.21 Million USD | -65.59% |
| 2020 Q2 | -6.77 Million USD | 46.73% |
| 2019 Q1 | -12.13 Million USD | -10.97% |
| 2019 Q4 | -12.71 Million USD | -9.24% |
| 2019 Q3 | -11.64 Million USD | 0.27% |
| 2019 Q2 | -11.67 Million USD | 3.81% |
| 2019 FY | -48.16 Million USD | -29.36% |
| 2018 Q2 | -9.15 Million USD | -8.76% |
| 2018 FY | -37.23 Million USD | -28.96% |
| 2018 Q4 | -10.93 Million USD | -25.25% |
| 2018 Q1 | -8.41 Million USD | 3.06% |
| 2018 Q3 | -8.73 Million USD | 4.62% |
| 2017 Q3 | -6.88 Million USD | -1.83% |
| 2017 Q4 | -8.68 Million USD | -26.03% |
| 2017 FY | -28.87 Million USD | -29.91% |
| 2017 Q1 | -6.65 Million USD | 0.0% |
| 2017 Q2 | -6.76 Million USD | -1.73% |
| 2016 FY | -22.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 100.603% |
| Allurion Technologies Inc. | -78.07 Million USD | 49.947% |
| Artivion, Inc. | 5.74 Million USD | 780.599% |
| Avanos Medical, Inc. | 4.2 Million USD | 1030.476% |
| Butterfly Network, Inc. | -145.61 Million USD | 73.161% |
| Butterfly Network, Inc. | -145.61 Million USD | 73.161% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 110.182% |
| Boston Scientific Corporation | 2.34 Billion USD | 101.668% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | -157.41% |
| CONMED Corporation | 130.78 Million USD | 129.881% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 102.547% |
| Paragon 28, Inc. | -37.3 Million USD | -4.747% |
| Glaukos Corporation | -128.7 Million USD | 69.635% |
| Globus Medical, Inc. | 133.14 Million USD | 129.352% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 2.957% |
| Integer Holdings Corporation | 167.33 Million USD | 123.355% |
| Medtronic plc | 5.14 Billion USD | 100.76% |
| Nevro Corp. | -99.3 Million USD | 60.648% |
| Owlet, Inc. | -28.63 Million USD | -36.491% |
| Penumbra, Inc. | 73.55 Million USD | 153.133% |
| Vicarious Surgical Inc. | -80.66 Million USD | 51.553% |
| Smith & Nephew plc | 425 Million USD | 109.195% |
| Sonendo, Inc. | -57.74 Million USD | 32.321% |
| STERIS plc | 836.11 Million USD | 104.674% |
| Stryker Corporation | 3.88 Billion USD | 101.005% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 103.059% |